Condition: Alzheimer Disease (AD) · Sponsor: Douglas Mental Health University Institute
This study will evaluate whether daridorexant, a DORA sleep medication, can support brain health by promoting the clearance of proteins linked to the development and progression of Alzheimer's disease. The trial is preventive and is open to participants who do not have Alzheimer's disease dementia, regardless of whether or not they experience sleep problems.
This description comes directly from the study's public registry record.
Jennifer Tremblay-Mercier, MSc · 855-888-4485 · prevenir.alzheimer@douglas.mcgill.ca
Nolan-Patrick Cunningham, BA · 15147616131 · nolan-patrick.cunningham.comtl@ssss.gouv.qc.ca
Always discuss trial participation with your own doctor first.
| Centre StoP-Alzheimer (Douglas Mental Health University Institute - Research Centre) | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07213349